Part D 2010 call letter reissued
Executive Summary
The latest version of the 2010 draft "call letter" to Medicare Part D plan sponsors maintains all the key formulary-related policy statements from the original version, including CMS objections to edits that impede beneficiary access to all approved indications of on-formulary drugs. The draft instructions for submitting bids for 2010 were originally released Jan. 8 (1"The Pink Sheet," Jan. 19, 2009, p. 13). It was withdrawn shortly thereafter by the new administration for review and reissued Jan. 23; comments on the draft are being accepted until March 6 and the final version is scheduled to be released March 30
You may also be interested in...
Part D In 2010: No Reference Pricing, More CMS Scrutiny Of Formulary Edits
The last CMS 1draft "call letter" to Medicare Part D contractors to be issued under the current administration emphasizes familiar themes - concern with information transparency and ensuring appropriate access to drugs - and includes little in the way of drug coverage policy changes
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.